Changeflow GovPing Pharma & Healthcare EBV Reactivation Longitudinal Cohort Study, 100...
Routine Notice Added Final

EBV Reactivation Longitudinal Cohort Study, 100 Adults, 18-29, Australia

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH registered observational cohort study NCT07536048 on ClinicalTrials.gov tracking EBV reactivation in 100 EBV seropositive adults aged 18-29 years in Australia. The prospective longitudinal study will follow participants over 6-12 months with no study interventions. Participants will undergo immunological and clinical data collection at designated study centers.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH registered a new observational cohort study on ClinicalTrials.gov focused on Epstein-Barr Virus reactivation. The study will enroll approximately 100 EBV seropositive adults aged 18-29 years at multiple centers across Australia and follow participants for 6-12 months.

This is a registry entry for an observational study and does not impose compliance obligations. Researchers and clinical sites in Australia conducting infectious disease or immunological research may find this study relevant for understanding EBV reactivation patterns in young adults.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years

Observational NCT07536048 Kind: OBSERVATIONAL Apr 17, 2026

Abstract

This multi-center, prospective, longitudinal cohort study is designed to gather immunological and clinical data on EBV reactivation in EBV seropositive adults aged 18 to 29 years.

This study will follow a cohort of approximately 100 EBV seropositive adults 18 to 29 years of age in Australia over a 6 or 12-month period.

Participants will not receive any study intervention (eg, study treatments, vaccines).

Conditions: Epstein-Barr Virus (EBV), Healthy Volunteers

Interventions: Investigational Procedure

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 17th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07536048

Who this affects

Applies to
Healthcare providers Clinical investigators
Industry sector
3254.1 Biotechnology
Activity scope
Clinical study design Participant enrollment Data collection
Geographic scope
Australia AU

Taxonomy

Primary area
Public Health
Operational domain
Clinical Operations
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!